Mirugen
Mirugen is a preclinical biotechnology company pioneering in vivo cell reprogramming therapies to treat inherited and age-related retinal diseases. By activating Müller glial cells’ regenerative potential, Mirugen aims to restore vision and reverse photoreceptor loss in conditions such as retinitis pigmentosa, Stargardt’s disease, and age-related macular degeneration.
Over 300 million people worldwide suffer from inherited or age-related retinal diseases, many of which lead to irreversible vision loss. Current treatments are limited to slowing progression or managing symptoms, with no approved therapies that restore lost photoreceptors. Mirugen’s regenerative approach—reprogramming Müller glia into functional photoreceptors—offers a transformative solution, potentially reversing blindness and restoring sight for millions of patients.
